GLP-1RAs, which are antidiabetic drugs, improve NAFLD and CVD in patients with type 2 diabetes mellitus by activating AMPK and SIRT6, key regulators of lipid, glucose, and cholesterol metabolism pathways [2326]
In some regions, it is classified as a research chemical and not approved for human use, while in others, it may be available by prescription for specific medical conditions
This suggests GLP-1 receptor activation in the brain may have secondary anti-inflammatory and thermoregulatory benefits independent of appetite suppression
Common side effects include: Nausea, especially in the early weeks Occasional vomiting or diarrhea Fatigue or mild headaches Redness or discomfort at the injection site Less common but more serious risks include: Pancreatitis Gallbladder issues Kidney concerns in patients with pre-existing conditions The key to safe treatment is proactive monitoring
395 Similarly, lncRNAs can act as competing endogenous RNAs (ceRNAs), sequestering miRNAs and affecting their regulatory functions
Nature 606 , 945952 (2022)
